15/10/2026
PRESS RELEASE 📢 | 𝗔 𝗻𝗲𝘄 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝗶𝗻 𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝘀𝘁𝗮𝗿𝘁𝘀 𝘁𝗼𝗱𝗮𝘆!
Today, we announce that the first patient in the U.S. has been implanted with the investigational MySalvia System in RECLAIM-II, our pivotal study in adults with resistant migraine.
For people living with resistant migraine, trying multiple preventive treatments does not always mean finding sufficient relief. The burden can remain profound.
RECLAIM-II will evaluate the safety and effectiveness of our purpose-built neuromodulation system in approximately 150 patients across more than 20 sites in the United States.
This first implantation in the U.S. represents years of work across our clinical program, and an important next step in building the rigorous evidence needed to understand the potential role of neuromodulation in migraine care.
We’re deeply grateful to the patients, investigators, clinical teams and everyone at Salvia who is making this study possible. Together, we’re moving closer to our mission of empowering people with migraine to reclaim their lives.
🔗 Read the full announcement: https://www.salviabioelectronics.com/news/salvia-bioelectronics-initiates-pivotal-study-with-first-patient-in-the-u-s-receiving-ultra-thin-neuromodulation-implant-for-resistant-migraine
𝘊𝘈𝘜𝘛𝘐𝘖𝘕 – 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘰𝘳 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦.
Press release - Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, today announced that the first patient has been implanted with the MySalvia System in RECLAIM-II, the company’s pivotal trial evaluating the...